Mabion S.A.

Warsaw Stock Exchange MAB.WA

Mabion S.A. Shares (Diluted, Weighted) for the year ending December 31, 2023: 16,162,326

Mabion S.A. Shares (Diluted, Weighted) is 16,162,326 for the year ending December 31, 2023, a 0.00% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Mabion S.A. Shares (Diluted, Weighted) for the year ending December 31, 2022 was 16,161,966, a 3.90% change year over year.
Mabion S.A. Shares (Diluted, Weighted) for the year ending December 31, 2021 was 15,555,287, a 13.36% change year over year.
Mabion S.A. Shares (Diluted, Weighted) for the year ending December 31, 2020 was 13,722,000, a 0.00% change year over year.
Mabion S.A. Shares (Diluted, Weighted) for the year ending December 31, 2019 was 13,721,917, a 4.83% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

Warsaw Stock Exchange: MAB.WA

Mabion S.A.

CEO	Mr. Krzysztof Kaczmarczyk
IPO Date	Aug. 10, 2010
Location	Poland
Headquarters	ul. gen. Mariana Langiewicza 60
Employees	241
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics

Description

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.

Key trends

Past 5 years